CS Paper Radar

Longitudinal Bayesian Learning of Continuous Disease Position across the Alzheimer's Disease Continuum

Yingying Zhang, Kun Zhao, Guodong Liu, Qi Huang, Pengfei Gu, Dongchul Kim, Erik Enriquez, Alex D. Leow, Paul M. Thompson, Heng Huang, Hongchang Gao, Liang Zhan, Haoteng Tang

cs.LG cs.AIq-bio.QM ·submitted 2026-08-19 20:41 UTC · v1

Abstract

Alzheimer's disease (AD) progresses as a continuous biological process, whereas most existing neuroimaging-based artificial intelligence methods remain limited to discrete diagnosis or clinical score prediction from cross-sectional imaging. In this work, we propose Disease Continuum Positioning (DCP), a longitudinal Bayesian Learning framework that continuously estimates disease severity from longitudinal diffusion tensor imaging (DTI). Specifically, DCP models disease severity as a low-dimensional probabilistic latent variable by jointly integrating longitudinal observations with weak clinical supervision, from which the proposed Disease Continuum Score (DCS) is derived to quantify an individual's position along the Alzheimer's disease continuum together with its associated uncertainty. Extensive experiments on the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort demonstrate that DCP consistently outperforms representative disease progression methods. More importantly, comprehensive validation analyses show that DCS accurately characterizes disease severity, exhibits strong clinical relevance, preserves longitudinal disease evolution, and predicts future disease conversion. These results suggest that DCS provides a quantitative imaging-derived representation for continuous assessment of Alzheimer's disease progression beyond conventional diagnostic labels and clinical scores.

Closest papers

Nearest neighbours by meaning across the whole index.

Multimodal-Conditioned Latent Diffusion Models for Spatiotemporal Brain MRI Forecasting

cs.CV cs.AI ·2026-10-18 ·Antonio Scardace, Silvia Ingala, Sebastiano Battiato, Daniele Ravì
publishedcode/data similarity 0.73
Abstract · Accepted to WACV 2027

Spatiotemporal forecasting of 3D anatomical changes is a critical generative vision challenge for modeling Alzheimer's Disease (AD) progression. While brain MRI forecasting from single-modality data has advanced, other key complementary multimodal biomarkers remain underutilized. In this work, we propose the Multimodal-Conditioned Latent Diffusion Model (MC-LDM), a novel framework for patient-specific brain MRI synthesis. MC-LDM leverages multimodal biomarkers---MRI, tau-PET, Clinical Dementia Rating (CDR), and APOE4---during training, but relies only on baseline MRI, APOE4, and patient metadata at inference, reflecting realistic clinical availability. Our contributions are threefold: (1) a Latent Diffusion Model (LDM) fine-tuned via Low-Rank Adaptation (LoRA) for data-efficient learning; (2) a multimodal conditioning that integrates molecular and clinical signals to model heterogeneous disease trajectories; and (3) auxiliary predictors estimating unobserved multimodal biomarkers from MRI features and patient covariates to condition the diffusion model, removing the need for these assessments at inference. Trained on 1,355 visits from 852 subjects in the Alzheimer's Disease Neuroimaging Initiative (ADNI), MC-LDM reduces average regional volumetric MAE by 18% over the second-best baseline on an independent test set of 664 visits. To our knowledge, MC-LDM represents the first diffusion-based framework to leverage multimodal priors for MRI forecasting. This conceptual advancement enables patient-specific trajectory generation that captures aspects of AD heterogeneity not observable from structural anatomy alone, bridging the gap between rich multimodal supervision and the strict constraints of routine clinical deployment. Code is available at: https://github.com/antonioscardace/MC-LDM.

0.43

Clinical Pathways Matter for Multimodal Deep Learning in Early Alzheimers Disease Detection

eess.IV ·2026-08-17 ·Yao Lu, Solveig Kristina Hammonds, Alvaro Fernandez-Quilez
published similarity 0.69
Abstract · Published

Identifying individuals at risk of Alzheimer's disease (AD), particularly in the preclinical and early stages, remains challenging. Although deep learning approaches based on structural MRI show promise as a non-invasive biomarker, existing multimodal models require task-specific training and depend on biomarkers that are not routinely available in clinical practice. Here, we propose a zero-shot multimodal framework based on SigLIP that combines structural MRI embeddings with text embeddings of routinely collected clinical variables for early AD risk stratification in individuals at preclinical or mild cognitive impairment (MCI) stages. We evaluated the approach in 416 individuals from the ADNI cohort (age: 72.73 +- 6.7). SigLIP was used without fine-tuning to extract MRI and clinical text embeddings, which were combined into multimodal representations for individual-level AD risk prediction within 4 years. We further compared the model performance in a single-visit and two-visit settings to assess the value of longitudinal information and framework scalability. In the single-visit setting, combining MRI embeddings with MMSE, age, and sex achieved an AUC of 0.91 +- 0.02, outperforming both a CSF A\b{eta}42-based model (AUC 0.73 +- 0.08) and an MMSE-based model (AUC 0.85 +- 0.22). In the two-visit setting, performance was maintained or improved, supporting the scalability of the approach to longitudinal data. These findings suggest that zero-shot multimodal fusion of structural MRI and routinely collected clinical variables may provide a practical and scalable strategy for early AD risk stratification without task-specific retraining.

0.48

AG-JEPA: Anatomically Guided Joint Embedding Predictive Architecture for Neurodegenerative Representation Learning

cs.CV cs.AI ·2026-11-13 ·Azad Singh, Ayantika Das, Amog Rao, Aiman Farooq, Anirban Porya +5 more
similarity 0.68
Abstract

Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent. However, during the transition from cognitively normal (CN) to mild cognitive impairment (MCI), the disease-related signals are often subtle and confined to only a few brain regions. Existing Joint Embedding Predictive Architecture (JEPA) models learn general structural representations but do not explicitly capture the anatomical regions affected in AD. We propose Anatomically Guided JEPA (AG-JEPA), which introduces anatomical tokens that interact with patch tokens during pretraining to learn region-specific representations from brain regions relevant to neurodegeneration. Building on this representation space, we further propose Prog-AG-JEPA, which models disease progression trajectory as a conditioned latent displacement within this space. We evaluate AG-JEPA across five downstream tasks spanning Alzheimer's disease diagnosis and progression prediction. AG-JEPA improves diagnosis and MCI prognosis, achieving an 8.4 percentage point AUROC gain over the strongest baseline on CN/MCI classification and a 7.1 percentage point gain on out-of-distribution CN/AD classification on the MR-RATE dataset, highlighting its effectiveness across both early-stage detection and cross-cohort generalization. For disease progression modeling, Prog-AG-JEPA consistently outperforms all baselines on future diagnosis and brain volume change prediction, demonstrating the value of anatomically grounded neurodegeneration representations for diagnosis and prognosis.

0.09

Covariate-Conditioned One-Step Diffusion for Multi-Horizon 3D Brain MRI Prediction in Aging and Neurodegeneration

eess.IV cs.AIcs.CVcs.LG ·2026-11-05 ·Natenaile Asmamaw Shiferaw, Ali Farki, Deepika Koundal, Jussi Tohka
code/data similarity 0.68
Abstract · 5 pages, 2 figures, 4 tables. Submitted to IEEE ISBI 2027

Predicting longitudinal brain changes from magnetic resonance imaging (MRI) can help characterize structural progression associated with aging and neurodegeneration. However, diffusion-based forecasting typically requires iterative denoising, limiting inference efficiency. We propose a covariate-conditioned one-step diffusion framework for multi-horizon prediction of 3D gray-matter density (GMD) maps. Rather than directly generating future anatomy, the model predicts longitudinal GMD changes through residual prediction in a single denoising step. The predicted changes are added to the baseline GMD map to reconstruct future anatomy. The model is conditioned on baseline anatomy, age, diagnosis, APOE4 allele count, and continuous follow-up time. Training combines mean squared error with a Pearson correlation loss to improve the spatial agreement between predicted and observed GMD changes. A unified model supports prediction horizons from 2 to 10 years. On the held-out ADNI test set, our method achieves a $Δ$-Pearson of 0.478, mean squared error (MSE) of $5.176 \times 10^{-3}$, and structural similarity index measure (SSIM) of 0.979, with $Δ$-Pearson reaching 0.582 at 10 years. Without retraining, external evaluation on AIBL yields a $Δ$-Pearson of 0.450, MSE of $4.016 \times 10^{-3}$, and SSIM of 0.985. Ablation studies further demonstrate the benefits of residual prediction, covariate conditioning, and correlation-based supervision. Code: https://github.com/natenaile/OneStepBrainMRI.

0.34

CoPoE: Multimodal Fusion via Decomposable Disease-Coordinate Product-of-Experts for Missing-Modality Alzheimer's Diagnosis

cs.LG cs.CV ·2026-10-08 ·Chihun An, Ikbeom Jang
publishedbenchmarkcode/data similarity 0.65
Abstract · Accepted at IEEE BIBM 2026

Multimodal Alzheimer's disease (AD) diagnosis benefits from integrating heterogeneous clinical, imaging, genomic, and biomarker evidence, but clinical cohorts frequently suffer from irregular modality missingness. Existing fusion methods often synthesize absent inputs, risking the introduction of artificial surrogates, or pool available signals into uninterpretable latent spaces. We present CoPoE (Disease-Coordinate Product-of-Experts), a disease-coordinate framework that maps multimodal evidence into a structured latent space partitioned into four distinct biological and clinical axes: genetic Risk, molecular Pathology, Neurodegeneration, and clinical Stage (R/P/N/S). Each observed modality parameterizes a diagonal Gaussian expert over the full RPNS vector, and a masked Product-of-Experts architecture fuses only the available modalities. Consequently, absent modalities add no factor to the fusion path, allowing the network to preserve a robust, decomposable posterior for any non-empty modality subset without synthetic imputation in the RPNS path. Through extensive missing-modality experiments on the ADNI dataset, CoPoE achieves the best all-modality performance and the highest mean AUROC across all 15 observed-subset evaluations among standardized missing-modality fusion baselines under a shared non-PET ADNI embedding benchmark, while substantially improving raw-probability ECE, Brier score, and NLL. Furthermore, PET-supervised probing shows evidence enrichment within the pathology (P) block under full modalities, with tau-related signal retained even when direct fluid biospecimen inputs are withheld. Our code is available at https://github.com/labhai/CoPoE.

0.44

Leakage-Controlled Multimodal Learning for Diagnosis and Progression Prediction in Alzheimer's Disease Research

cs.LG ·2026-10-07 ·Akeem Temitope Otapo, Ghazaleh Khodabandelou, Zuheng Ming, Alice Othmani
similarity 0.65
Abstract

Alzheimer's disease prediction involves irregular visits, heterogeneous measurements and incomplete modalities. This study presents a multimodal multitask framework combining an adapted SFCN MRI encoder, four causal clinical Transformers, shared fusion and task-specific ODE-GRU dynamics. Fine-tuning and LoRA adapt the final two MRI blocks. Task-DRO balances task losses, while Group-CVaR targets cohort and comorbidity strata. Branch-specific input controls, subject-grouped partitions and empirical causality checks support longitudinal evaluation. Across 2,649 subjects and 17,317 visits from ADNI, OASIS-2 and MIRIAD, internal validation yields diagnosis, stage-1 progression and first-stage-1-visit progression AUROCs of 0.935 +/- 0.002, 0.884 +/- 0.003 and 0.870 +/- 0.005, respectively (mean +/- SD across three seeds). Corresponding hybrid AUROCs are 0.951, 0.909 and 0.896. Next-visit MMSE mean absolute error (MAE) is 1.61 points; worst-stratum diagnosis AUROC is 0.827 +/- 0.008. Sampled ADNI explanations identify task-specific input dependence. OASIS-3 external validation yields network and hybrid diagnosis AUROCs of 0.763 and 0.767, hybrid next-visit progression AUROC of 0.764, diagnosis calibration error decreasing from 0.197 to 0.052, and next-visit MMSE MAE of 0.86. Seed-42 paired ablations of six components yield pooled diagnosis and progression AUROC differences between -0.004 and +0.004; removing clinical encoder inputs lowers diagnosis AUROC by 0.272. The framework integrates longitudinal prediction, missing-modality handling, auxiliary comorbidity modelling and subgroup evaluation within a common pipeline.

0.11

Cross-disorder Learning of Imaging-derived Joint Mophometric Markers in Alzheimer's and Parkinson's Diseases

cs.LG q-bio.QMq-bio.NC ·2026-10-19 ·Yuji Zhao, Boris Gutman
code/datahot direction similarity 0.64
Abstract

As two most prevalent neurodegenerative diseases (NDDs), Alzheimer's disease (AD) and Parkinson's disease (PD) shared commonalities both in symptomology and pathophysiology. However, to what extent and in what way these two distinct disorders overlap remain underexplored. In this study, we propose an explicit, interpretable and spatially adaptive transfer learning framework to elucidate the morphometric biomarkers linked to AD and PD. We applied such high-dimensional machine learning model to two most popular open-source neuroimaging datasets, i.e., Alzheimer's Disease Neuroimaging Initiative (ADNI) and Parkinson's Progression Markers Initiative (PPMI). On the one hand, our cross-disorder classifier revealed neuro-anatomical alteration patterns well aligning with previous neuroimaging research findings and underscoring patients' clinical presentations. On the other hand, the spatially adaptive trained classifier using shared prior achieved statistically superior diagnostic performance compared to respective individual models, which further highlights the cross-disorder framework's efficacy on modeling limited-size datasets across disease domains.

0.37

Modality Contribution Score - A Per-Patient Framework for Quantifying the Relative Diagnostic Contribution of Structural MRI and Amyloid PET in Alzheimer's Disease

eess.IV cs.AIcs.CVcs.LG ·2026-08-23 ·Dawa Chyophel Lepcha, Aaliya Ali, Sophie A. Martin, Deepika Koundal, Pierrick Coupe +1 more
similarity 0.63
Abstract · 15 pages, 7 figures, Under review

Multimodal neuroimaging combining structural MRI and positron emission tomography (PET) captures complementary structure-function relationships across the Alzheimer's disease (AD) continuum, yet existing artificial intelligence systems produce a single diagnostic label without quantifying which imaging modality drove that decision for a specific patient. We introduce the Modality Contribution Network (MCNet) and the Modality Contribution Score (MCS), the first per-patient attribution framework quantifying the shift in modality dominance from structural atrophy to amyloid and metabolic dysfunction across the cognitively normal to MCI to AD continuum. MCS is normalised to unity per subject via modality ablation (MCS_MRI_i + MCS_PET_i = 1.0 for every subject i), providing an interpretable, clinically actionable score that fluid biomarkers cannot supply. Applied to 327 ADNI-3 participants balanced across cognitively normal, mild cognitive impairment, and AD groups, MCNet achieved competitive three-class staging performance (AUC=0.881). The MCS revealed a statistically significant monotonic gradient (Kruskal-Wallis p<0.0001), with increasing PET dominance from cognitively normal (MCS_PET 0.412+/-0.229) through MCI (0.489+/-0.289) to AD (0.671+/-0.426), validated against amyloid SUVR (r=0.172, p=0.006) and FDG metabolic biomarkers (r=-0.287, p=0.0005) from separate imaging pipelines. External replication in 1,073 independent OASIS-3 subjects confirmed cross-cohort generalisability (H=166.99, p<0.0001, eta^2=0.156). A mechanistic comparison with SHAP demonstrated that ablation-based MCS captures clinically meaningful modality dependence that deviation-based methods cannot. These findings position MCNet as a foundation for personalised imaging decisions, clinical trial stratification, and trustworthy AI in dementia care.

0.32